BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/14/2019 6:53:01 AM | Browse: 804 | Download: 983
 |
Received |
|
2019-01-29 02:39 |
|
Peer-Review Started |
|
2019-01-29 04:32 |
|
First Decision by Editorial Office Director |
|
2019-03-27 03:11 |
|
Return for Revision |
|
2019-03-27 07:24 |
|
Revised |
|
2019-03-28 12:32 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-04-19 07:10 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-04-20 02:04 |
|
Articles in Press |
|
2019-04-20 02:04 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-29 02:18 |
|
Publish the Manuscript Online |
|
2019-06-06 08:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Michiel Dirk Voskuil, Amber Bangma, Rinse Karel Weersma and Eleonora Anna Margaretha Festen |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michiel Dirk Voskuil, MD, Research Fellow, Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, PO Box 30001, Hanzeplein 1, Groningen 9713 GZ, Netherlands. m.d.voskuil@umcg.nl |
| Key Words |
Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Pharmacogenetics; Personalized medicine |
| Core Tip |
In recent years, strong pharmacogenetic associations for drugs used in the management of inflammatory bowel disease (IBD) have been identified. However, the implementation of pre-treatment pharmacogenetic testing into clinical guidelines has been challenging. Particular groups of patients are needlessly exposed to (expensive) drugs that are either ineffective or harmful. Pre-treatment screening for TPMT and NUDT15 genetic variation should be incorporated into clinical IBD management guidelines. Therapeutic recommendations based on HLA genetic variants, conferring risk for thiopurine-induced pancreatitis and immunogenicity to tumor necrosis factor-antagonists, respectively, should be further evaluated. |
| Publish Date |
2019-06-06 08:31 |
| Citation |
Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol 2019; 25(21): 2539-2548 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i21/2539.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i21.2539 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
